Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 6, 2013

Ajinomoto Moves into CDMO Market

  • Ajinomoto agreed to take over Althea Technologies, a contract development and manufacturing organization (CDMO), by acquiring all of the company’s capital stock for $175 million. According to an Ajinomoto official, the CMDO market is estimated at $2.3 billion and double-digit growth is expected.

    “In combining Ajinomoto’s experience in biotechnology, together with Althea's sophisticated technology, experienced personnel, and expertise in cGMP manufacturing, we aspire to expand our business for biopharmaceuticals manufacturing in the U.S. market and strengthen our advanced biomedical businesses,” said Masatoshi Ito, Ajinomoto’s president and CEO.

    This year Ajinomoto has made a number of deals that confirm its keen interest in the biomedical field. Just last week it announced plans to invest approximately $13.9 million to double production capacity for amino acids for use in pharmaceuticals and foods at its subsidiary Shanghai Ajinomoto Amino Acid Co. The expansion is scheduled to come on line in October.

    In February, Ajinomoto Genexine, its joint venture with Genexine Co., reported plans to construct a new plant in the South Korea for cell culture media for biopharmaceutical production. The new plant, which will cost about $30 million, is scheduled to begin full-scale operation in July 2014.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »